Search - tctmd.com

Displaying 861 - 880 of 1861

Sort: Relevancy | Date

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

Presentation TCT 2019

STOPDAPT, SMART-CHOICE, and TWILIGHT: Will These Trials Change Your Clinical Practice?

Presenter: Aditya Kapoor

September 28, 2019

Presentation TCT 2019

Death Following DCB Use – Not! Clinical Data from Coronary Trials

Presenter: Bruno Scheller

September 28, 2019

Presentation TCT 2019

Intravenous Platelet Inhibition for PCI: Drug Description and Clinical Outcomes From Randomized Trials and Registries

Presenter: Matthew Price

September 27, 2019

Presentation TCT 2019

FFR-CT State of the Art Clinical Study Evidence and Ongoing/Planned Trials

Presenter: Manesh Patel

September 27, 2019

Presentation TCT 2019

ABSORB 5-Year Pooled Analysis: Improving Very Late Outcomes of the Absorb Bioresorbable Scaffold in Coronary Artery Disease From 4 Randomized Trials

Presenter: Gregg Stone

September 27, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

Innovation Gone Wild - Next-Generation TRIGUARD Cerebral Embolic Protection During TAVR: Technology Review and Status of Ongoing Clinical Trials

Presentation TCT 2019

Next-Generation TRIGUARD Cerebral Embolic Protection During TAVR: Technology Review and Status of Ongoing Clinical Trials

Presenter: Tamim Nazif

September 27, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Presentation TCT 2019

Polymer-Free DES: Lessons Learned From Recent Trials

Presenter: Michael Maeng

September 26, 2019

Presentation TCT 2019

Clinical Trial Snapshots: Top DES Randomized Trials of the Last 2 Years

Presenter: Mamas Mamas

September 26, 2019

News Industry News

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

September 25, 2019

News Daily News

SCAI Shock Definition Tracks Well With Mortality in Cardiac ICU

Todd Neale

September 24, 2019

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Caitlin E. Cox

September 20, 2019

Advertisement

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

STOPDAPT, SMART-CHOICE, and TWILIGHT: Will These Trials Change Your Clinical Practice?

Death Following DCB Use – Not! Clinical Data from Coronary Trials

Intravenous Platelet Inhibition for PCI: Drug Description and Clinical Outcomes From Randomized Trials and Registries

FFR-CT State of the Art Clinical Study Evidence and Ongoing/Planned Trials

ABSORB 5-Year Pooled Analysis: Improving Very Late Outcomes of the Absorb Bioresorbable Scaffold in Coronary Artery Disease From 4 Randomized Trials

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

Next-Generation TRIGUARD Cerebral Embolic Protection During TAVR: Technology Review and Status of Ongoing Clinical Trials

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Polymer-Free DES: Lessons Learned From Recent Trials

Clinical Trial Snapshots: Top DES Randomized Trials of the Last 2 Years

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

SCAI Shock Definition Tracks Well With Mortality in Cardiac ICU

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content